REGAL REXNORD CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that REGAL REXNORD CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Jan 3, 2015 | $3.26B | Mar 4, 2015 |
| FY2014 | Dec 28, 2013 | $3.10B | Mar 4, 2015 |
| FY2014 | Dec 29, 2012 | $3.17B | Mar 4, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $6.25B | Feb 26, 2024 |
| FY2023 | Dec 31, 2022 | $5.22B | Feb 26, 2024 |
| FY2021 | Jan 1, 2022 | $1.22B | Mar 2, 2022 |
| FY2021 | Oct 2, 2021 | $892.70M | Mar 2, 2022 |
| FY2021 | Jul 3, 2021 | $886.90M | Mar 2, 2022 |
| FY2021 | Apr 3, 2021 | $814.10M | Mar 2, 2022 |
| FY2021 | Jan 2, 2021 | $780.50M | Mar 2, 2022 |
| FY2021 | Sep 26, 2020 | $758.20M | Mar 2, 2022 |
| FY2021 | Jun 27, 2020 | $634.10M | Mar 2, 2022 |
| FY2021 | Mar 28, 2020 | $734.20M | Mar 2, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.22B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.19B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $2.07B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $1.67B | Feb 21, 2025 |
| FY2021 | Jan 1, 2022 | $334.20M | Mar 2, 2022 |
| FY2021 | Oct 2, 2021 | $254.60M | Mar 2, 2022 |
| FY2021 | Jul 3, 2021 | $251.50M | Mar 2, 2022 |
| FY2021 | Apr 3, 2021 | $245.40M | Mar 2, 2022 |
| FY2021 | Jan 2, 2021 | $213.50M | Mar 2, 2022 |
| FY2021 | Sep 26, 2020 | $221.60M | Mar 2, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $279.50M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $196.20M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | ($57.40M) | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $488.90M | Feb 21, 2025 |
| FY2021 | Jan 1, 2022 | ($4.80M) | Mar 2, 2022 |
| FY2021 | Oct 2, 2021 | $69.50M | Mar 2, 2022 |
| FY2021 | Jul 3, 2021 | $79.60M | Mar 2, 2022 |
| FY2021 | Apr 3, 2021 | $65.60M | Mar 2, 2022 |
| FY2021 | Jan 2, 2021 | $50.40M | Mar 2, 2022 |
| FY2021 | Sep 26, 2020 | $65.00M | Mar 2, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $680.80M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $630.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $377.10M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $690.40M | Feb 21, 2025 |
| FY2021 | Jan 1, 2022 | $18.90M | Mar 2, 2022 |
| FY2021 | Oct 2, 2021 | $107.40M | Mar 2, 2022 |
| FY2021 | Jul 3, 2021 | $109.00M | Mar 2, 2022 |
| FY2021 | Apr 3, 2021 | $97.10M | Mar 2, 2022 |
| FY2021 | Jan 2, 2021 | $74.20M | Mar 2, 2022 |
| FY2021 | Sep 26, 2020 | $90.00M | Mar 2, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $198.70M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $176.40M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $171.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $106.60M | Feb 21, 2025 |
| FY2023 | Jan 1, 2022 | $74.50M | Feb 26, 2024 |
| FY2022 | Jan 2, 2021 | $67.00M | Feb 24, 2023 |
| FY2021 | Dec 28, 2019 | $64.60M | Mar 2, 2022 |
| FY2020 | Dec 29, 2018 | $29.30M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $29.90M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $29.50M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $990.80M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $609.40M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $715.30M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $436.20M | Feb 21, 2025 |
| FY2023 | Jan 1, 2022 | $357.70M | Feb 26, 2024 |
| FY2022 | Jan 2, 2021 | $435.40M | Feb 24, 2023 |
| FY2021 | Dec 28, 2019 | $408.50M | Mar 2, 2022 |
| FY2020 | Dec 29, 2018 | $362.70M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $291.90M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $442.30M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.70M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $109.50M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $119.10M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $83.80M | Feb 21, 2025 |
| FY2023 | Jan 1, 2022 | $54.50M | Feb 26, 2024 |
| FY2022 | Jan 2, 2021 | $47.50M | Feb 24, 2023 |
| FY2021 | Dec 28, 2019 | $92.40M | Mar 2, 2022 |
| FY2020 | Dec 29, 2018 | $77.60M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $65.20M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $65.20M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.92B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $14.03B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $15.43B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $10.27B | Feb 26, 2024 |
| FY2022 | Jan 1, 2022 | $10.37B | Feb 24, 2023 |
| FY2021 | Jan 2, 2021 | $4.59B | Mar 2, 2022 |
| FY2020 | Dec 28, 2019 | $4.43B | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $4.62B | Feb 26, 2020 |
| FY2018 | Dec 30, 2017 | $4.39B | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $4.36B | Feb 26, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.84B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $6.26B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $6.34B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $6.39B | Feb 26, 2024 |
| FY2022 | Jan 1, 2022 | $6.37B | Feb 24, 2023 |
| FY2021 | Jan 2, 2021 | $2.54B | Mar 2, 2022 |
| FY2020 | Dec 28, 2019 | $2.35B | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $2.31B | Feb 26, 2020 |
| FY2018 | Dec 30, 2017 | $2.33B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $2.04B | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.61B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $6.46B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $6.55B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $4.02B | Feb 21, 2025 |
| FY2023 | Jan 1, 2022 | $4.04B | Feb 26, 2024 |
| FY2022 | Jan 2, 2021 | $1.52B | Feb 24, 2023 |
| FY2021 | Dec 28, 2019 | $1.50B | Mar 2, 2022 |
| FY2020 | Dec 29, 2018 | $1.51B | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $1.48B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.45B | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.23B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.04B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $1.98B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $2.13B | Feb 26, 2024 |
| FY2022 | Jan 1, 2022 | $1.91B | Feb 24, 2023 |
| FY2021 | Jan 2, 2021 | $2.01B | Mar 2, 2022 |
| FY2020 | Dec 28, 2019 | $1.89B | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $1.78B | Feb 26, 2020 |
| FY2018 | Dec 30, 2017 | $1.61B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.45B | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $521.70M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $393.50M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $574.00M | Feb 21, 2025 |
| FY2024 | Dec 31, 2022 | $688.50M | Feb 21, 2025 |
| FY2023 | Jan 1, 2022 | $672.80M | Feb 26, 2024 |
| FY2021 | Jan 2, 2021 | $611.30M | Mar 2, 2022 |
| FY2020 | Dec 28, 2019 | $331.40M | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $248.60M | Feb 26, 2020 |
| FY2018 | Dec 30, 2017 | $139.60M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $284.50M | Feb 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.82B | Feb 20, 2026 |
| FY2024 | Dec 31, 2024 | $5.50B | Feb 21, 2025 |
| FY2023 | Dec 31, 2023 | $6.38B | Feb 26, 2024 |
| FY2023 | Dec 31, 2022 | $2.02B | Feb 26, 2024 |
| FY2022 | Jan 1, 2022 | $1.92B | Feb 24, 2023 |
| FY2021 | Jan 2, 2021 | $1.07B | Mar 2, 2022 |
| FY2020 | Dec 28, 2019 | $1.14B | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $1.31B | Feb 26, 2020 |
| FY2018 | Dec 30, 2017 | $1.14B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.41B | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 21, 2025 |
| FY2021 | Jan 1, 2022 | 0 | Mar 2, 2022 |
| FY2021 | Oct 2, 2021 | 1 | Mar 2, 2022 |
| FY2021 | Jul 3, 2021 | 1 | Mar 2, 2022 |
| FY2021 | Apr 3, 2021 | 1 | Mar 2, 2022 |
| FY2021 | Jan 2, 2021 | 1 | Mar 2, 2022 |
| FY2021 | Sep 26, 2020 | 1 | Mar 2, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 21, 2025 |
| FY2021 | Jan 1, 2022 | 0 | Mar 2, 2022 |
| FY2021 | Oct 2, 2021 | 1 | Mar 2, 2022 |
| FY2021 | Jul 3, 2021 | 1 | Mar 2, 2022 |
| FY2021 | Apr 3, 2021 | 1 | Mar 2, 2022 |
| FY2021 | Jan 2, 2021 | 1 | Mar 2, 2022 |
| FY2021 | Sep 26, 2020 | 1 | Mar 2, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 66.40M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 66.30M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 66.30M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 66.20M | Feb 26, 2024 |
| FY2022 | Jan 1, 2022 | 67.60M | Feb 24, 2023 |
| FY2021 | Jan 2, 2021 | 40.60M | Mar 2, 2022 |
| FY2020 | Dec 28, 2019 | 40.80M | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | 42.80M | Feb 26, 2020 |
| FY2018 | Dec 30, 2017 | 44.30M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 44.80M | Feb 27, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $93.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $92.80M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $90.90M | Feb 21, 2025 |
| FY2023 | Jan 1, 2022 | $335.60M | Feb 26, 2024 |
| FY2022 | Jan 2, 2021 | $48.70M | Feb 24, 2023 |
| FY2021 | Dec 28, 2019 | $48.90M | Mar 2, 2022 |
| FY2020 | Dec 29, 2018 | $47.20M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $44.50M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $42.10M | Feb 26, 2019 |